Myriad Genetics Inc
Most Recent
Myriad Genetics Up after UnitedHealth’s Favorable Decision
Yesterday, Myriad Genetics submitted an 8K filing with the SEC announcing a favorable coverage decision by UnitedHealth Group.
Myriad Stock Rose on FDA Supplementary Premarket Approval
On June 18, Myriad Genetics stock rose ~1.9% after the FDA accepted its BRACAnalysis CDx test for review.
Vectra DA Could Be Solid Growth Driver for Myriad Genetics in 2018
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) Vectra DA test reported revenues close to $16 million.
Myriad Genetics Saw Positive Results from GeneSight Trial
Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.
Reimbursement for Myriad Genetics’ GeneSight in Fiscal 2018
In fiscal 2018, Myriad Genetics (MYGN) expects to witness rapid expansion in reimbursement for GeneSight based on positive results of the 1,200-patient pharmacogenomic study.
Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.
EndoPredict Posted Robust Demand Trends in US in Fiscal 1Q18
Myriad Genetics (MYGN) estimated the total addressable market size of its next-generation RNA expression test to be close to $0.9 billion.
Disease-Specific Panels Key to Myriad Genetics’ Growth Strategy
Myriad Genetics (MYGN) reported 40% year-over-year growth in volumes of disease-specific panels sold in fiscal 2017.
What Could Boost Adoption of Prolaris in 2018?
In the first quarter of 2018, Myriad Genetics’ (MYGN) Prolaris reported revenues close to $2.9 million, which is flat growth on a year-over-year (or YoY) basis.
BRACAnalysis CDx Received FDA Approval for Ovarian Cancer Indication
On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).
Companion Diagnostics May Be Major Opportunity for Myriad Genetics
Myriad Genetics (MYGN) expects to attain a penetration level of 4% in the companion diagnostics segment by 2020.
This Could Be a Solid Growth Driver for Myriad Genetics in 2018
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
Myriad Genetics Expected to Report Flat Revenue Growth in Fiscal 2018
Myriad Genetics (MYGN) expects to report revenues in the range of $750 million–$770 million in fiscal 2018 (ended June 30, 2018).
How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?
Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.
The Rise of Amgen Stock in 2Q17
Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.
Agios Stock Rises on Higher Trading Volumes on June 8
Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.
What Are IBB’s Holdings’ Moving Averages?
On May 27, 2016, 17% of the iShares Nasdaq Biotechnology ETF’s (IBB) stocks were trading above their 20-day moving averages.
Seattle Genetics’ Valuation: How Does It Compare?
We believe that the enterprise-value-to-revenue multiple is the best measure for valuing Seattle Genetics (SGEN) and similar companies.
IBB Mid-Caps: Medicines Company’s Carbavance, Fast-Track Status
In a press release, the Medicines Company (MDCO) announced that the FDA has granted fast-track status to Carbavance for the treatment of complicated urinary tract infections.
Pomalyst and Abraxane Revenues Are Critical for Celgene
Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.
Agios Initiates Phase 1b Trial of AG-221 or AG-120: Stock Up 14%
Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.
Outlook for PBE’s Biotechnology Subsectors
PBE’s biotechnology subsector is trading below its 100-day moving average by 3.0%, but above it 20-day and 50-day averages by 1.3% and 4.0%, respectively.
Horizon Rose and Outperformed IBB’s Mid-Cap Stocks
Horizon Pharma rose 5.4% on November 16, 2015. The stock rose due to the update at the shareholder meeting regarding the Depomed acquisition.
Myriad Genetics: Top Performer in the Biotechnology Subgroup
Myriad Genetics (MYGN) rose 9% on November 4, 2015. It reported its fiscal 1Q16 results. Myriad Genetics reported revenue of $183.5 million.
Moving Averages of XBI’s Holdings Have Improved
The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.
Grifols and Myriad Traded above the 100-Day Moving Averages
Grifols (GRFS) only fell by 0.34%. It bucked the trend. There were talks that Moody’s upgraded the ratings from “negative” to “stable.”
XBI’s Moving Averages: The Massive Plummet Last Week
XBI’s moving average took a hit in the week ended September 25, and most of its stocks were trading below all the moving averages. Compared to the previous week, the fall was massive.
Iridian nearly doubles its holdings in Lexmark International
Iridian Asset Management has increased its holdings in Lexmark International, Inc. (LXK) by 49%. This represents a 10.4% passive stake in the company.
AOL gets 45% boost in Iridian Asset Management
Iridian Asset Management’s position in AOL increased by 45%, increasing its shares from 5,075,812 to 7,369,542. Iridian has a 9.5% passive stake in AOL.
Halozyme Therapeutics gets huge 60% increase in Iridian holdings
Iridian Asset Management now holds 11,625,215 shares of Halozyme Therapeutics Inc. (HALO), a huge 60% increase. The fund has a 9% stake in the company.
Omnicare gets 18% increase in Iridian
Iridian increased its shares in Omnicare by approximately 18%, from 5,047,158 shares to 5,948,816. The fund holds a 6.1% passive stake in Omnicare.